Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | UGCG | Q16739 | 2/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606950 | 1.00 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL2186409 | 1.00 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL334304 | 1.00 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL334897 | 0.89 | MEN1 (0.64) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL15516358 | 0.88 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL334794 | 0.88 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL12903278 | 0.88 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL31549217 | 0.86 | MEN1 (0.60) | MEN1KMT2ATSHRTAAR1TDP1 | |
| SCHEMBL8478562 | 0.86 | MEN1 (0.60) | MEN1KMT2ATSHRTAAR1TDP1 | |
| SCHEMBL14250237 | 0.86 | MEN1 (0.55) | MEN1KMT2ATSHRTAAR1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250243143-A1 | 1,3-Fatty Diol Compounds And Derivatives Thereof | AGAIN BIO APS (DK) | 2025-07-31 | — | — | US | disclosed |
| CN-112437768-B | Novel functionalized lactams as modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-06-24 | — | — | CN | disclosed |
| US-12304883-B2 | 1,3-fatty diol compounds and derivatives thereof | GENOMATICA, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-114773160-B | 1, 3-Aliphatic diol compound and derivative thereof | 基因组股份公司 | 2025-03-07 | — | — | CN | disclosed |
| US-11964935-B2 | Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2024-04-23 | — | — | US | disclosed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2342192-A2 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | Psychogenics Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010045212-A2 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INCSTATUTS (US) | 2010-04-22 | — | — | WO | disclosed |
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1569934-B1 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060052408-A1 | Cyclopropyl compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1569934-A2 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004055010-A2 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR1B, HTR7, HTR6 | MEN1 3743/4885KMT2A 3250/4885TSHR 92/4885 |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | ENTPD5, ENTPD1, NT5E | MEN1 2174/4885KMT2A 2995/4885TSHR 2133/4885 |
| US-20250243143-A1 | 1,3-Fatty Diol Compounds And Derivatives Thereof | DGAT1, DGAT2, DSG1 | MEN1 3510/4885KMT2A 1008/4885TSHR 4725/4885 |
| US-12304883-B2 | 1,3-fatty diol compounds and derivatives thereof | DGAT1, DGAT2, DSG1 | MEN1 3510/4885KMT2A 1008/4885TSHR 4725/4885 |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR5A | MEN1 2505/4885KMT2A 2348/4885TSHR 91/4885 |
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, TPH2 | MEN1 3067/4885KMT2A 1855/4885TSHR 170/4885 |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | MEN1 4482/4885KMT2A 2367/4885TSHR 244/4885 |
| US-20060052408-A1 | Cyclopropyl compounds as ccr5 antagonists | CCR5, CCR1, CCL5 | MEN1 4782/4885KMT2A 4796/4885TSHR 3576/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | MEN1 4482/4885KMT2A 2367/4885TSHR 244/4885 |
| US-11964935-B2 | Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom | LSS, F2R, CFTR | MEN1 4067/4885KMT2A 4463/4885TSHR 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.